Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Friday, May 12th.
According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
Several other equities analysts also recently commented on ADMS. Mizuho reiterated a “buy” rating and set a $26.00 price target on shares of Adamas Pharmaceuticals in a report on Tuesday, February 21st. Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a report on Friday, May 12th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $28.50.
Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) traded up 1.39% on Friday, hitting $17.49. 165,769 shares of the stock traded hands. The stock’s market cap is $391.06 million. The stock has a 50-day moving average price of $16.46 and a 200 day moving average price of $16.63. Adamas Pharmaceuticals has a 12-month low of $12.10 and a 12-month high of $19.50.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, meeting the consensus estimate of ($0.72). Adamas Pharmaceuticals had a negative return on equity of 45.19% and a negative net margin of 10,499.65%. During the same quarter in the prior year, the firm earned ($0.65) EPS. On average, analysts anticipate that Adamas Pharmaceuticals will post ($3.47) earnings per share for the current fiscal year.
WARNING: “Adamas Pharmaceuticals, Inc. (ADMS) Stock Rating Lowered by Zacks Investment Research” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.com-unik.info/2017/06/17/adamas-pharmaceuticals-inc-adms-downgraded-by-zacks-investment-research-to-sell-updated-updated-updated.html.
In other news, CEO Gregory T. Went sold 2,807 shares of the firm’s stock in a transaction on Tuesday, March 21st. The shares were sold at an average price of $17.03, for a total value of $47,803.21. Following the sale, the chief executive officer now owns 166,526 shares in the company, valued at $2,835,937.78. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders sold 4,256 shares of company stock worth $72,480. 29.00% of the stock is currently owned by corporate insiders.
Several large investors have recently made changes to their positions in ADMS. JPMorgan Chase & Co. increased its stake in shares of Adamas Pharmaceuticals by 4.9% in the third quarter. JPMorgan Chase & Co. now owns 163,450 shares of the specialty pharmaceutical company’s stock valued at $2,683,000 after buying an additional 7,651 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Adamas Pharmaceuticals during the third quarter valued at about $219,000. Brenner West Capital Advisors LLC increased its stake in shares of Adamas Pharmaceuticals by 15.0% in the third quarter. Brenner West Capital Advisors LLC now owns 1,169,275 shares of the specialty pharmaceutical company’s stock valued at $19,188,000 after buying an additional 152,275 shares during the last quarter. Ardsley Advisory Partners bought a new stake in shares of Adamas Pharmaceuticals during the third quarter valued at about $246,000. Finally, Great Point Partners LLC bought a new stake in shares of Adamas Pharmaceuticals during the third quarter valued at about $42,688,000. Institutional investors and hedge funds own 75.72% of the company’s stock.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Adamas Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Adamas Pharmaceuticals Inc. and related companies.